- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$123.03 BnMarket Estimate, 2026
$132.27 BnMarket Forecast, 2034
$236.08 BnCAGR, 2026–2034
7.51%North America Biologics Market Report: Size, Share, Trends & Forecast (2026–2034)
- Market Scope: Comprehensive regional evaluation of the North American biologics market spanning source types (microbial, mammalian), product categories (monoclonal antibodies, vaccines, recombinant proteins, RNA/molecular therapies), manufacturing methodologies (outsourced, in-house), disease indications, and country-level adoption metrics.
- Market Valuation: Valued at USD 123.03 billion in 2025, estimated at USD 132.27 billion in 2026, and projected to reach USD 236.08 billion by 2034, growing at a steady CAGR of 7.51% during the forecast period from 2026 to 2034.
- Primary Growth Drivers: Escalating prevalence of chronic and autoimmune disorders, robust government funding for biomedical research, surging preference for targeted precision medicines, and continuous bioprocessing and cell line advancements.
Key North America Biologics Market Segment Metrics (2026–2034)
| Category | Leading Segment / Position | Fastest-Growing / Prominent Trend |
|---|---|---|
| By Product | Monoclonal Antibodies — dominates revenue share owing to widespread therapeutic adoption across oncology and immunology | Antisense, RNAi, & Molecular Therapies — expanding rapidly with next-generation gene-based biomedical innovations |
| By Manufacturing | In-House Manufacturing — captures majority share as major biopharma firms retain control over core production scales | Outsourced Manufacturing — scaling via strategic partnerships with specialized contract development and manufacturing organizations (CDMOs) |
| By Country | United States — leads the North American marketplace anchored by dense biotech networks and intensive R&D investments | Canada & Rest of North America — registering steady growth driven by expanding clinical trial infrastructure and supportive policies |
Major North American Biologics Companies & Competitive Landscape
Market Structure: A highly competitive, innovation-driven sector featuring prominent global pharmaceutical leaders focusing on large-molecule pipelines, advanced expression systems, and extensive clinical studies.
Key Companies: Johnson & Johnson (J&J), F. Hoffmann-La Roche, Bristol-Myers Squibb, GlaxoSmithKline, AbbVie, Amgen, Sanofi, Eli Lilly and Company, Merck & Co., and Pfizer Inc.
North America Biologics Market Size
The North America biologics market size was valued at USD 123.03 billion in 2025 and is anticipated to reach USD 132.27 billion in 2026 from USD 236.08 billion by 2034, growing at a CAGR of 7.51% during the forecast period from 2026 to 2034.
Government initiatives, actions to create novel techniques, Y-O-Y rise in the incidence of chronic diseases, rising healthcare costs, and rising prevalence to encourage outstanding treatment processes are all driving the global biologics market forward.
The market's growth rate is predicted to be aided by expanding acceptance of new medicines, rising demand for biologic medications, and increasing patent expirations. Biologics offer a wide range of uses in targeted therapies and can aid in treating various medical diseases when other treatments are unavailable. In addition, gene-based and cellular biologics are essential components of biomedical research, which will boost the market's growth pace.
Furthermore, the expanding global size of pharmaceutical firms and government attempts to raise public knowledge about the availability of various treatment processes for targeted disorders significantly impact the market's growth rate. Additionally, the efficacy of oral drugs for disorders including Crohn's and rheumatoid arthritis has grown, encouraging patients to try new treatments. As a result, the biologics market's growth rate will ultimately accelerate. The market demand is also fueled by the growing elderly population and the growing need to reduce the cost of treatment operations. In addition, people's preference for tablets over needles is accelerating market growth. Finally, the market's growth rate is also being boosted by technological improvements.
Introducing cutting-edge medicines with cutting-edge technology is expected to open up new prospects for the industry. Shortly, a decrease in the need for small molecule medication R&D activities is predicted to boost the demand for biologics.
Long-term usage of biologics also causes issues, including blood pressure abnormalities, gastrointestinal troubles, respiratory problems, and other steadily reduce the market demand.
The manufacturing process for biologics medications is quite complicated, which continues to be a significant stumbling block for the biologics market's growth. In addition, the biologics market's growth pace is slowing due to lower turnover for clinical studies.
REGIONAL ANALYSIS
Geographically, the North American biologics industry has led the worldwide biologics market in revenue generation. In healthcare biotechnology, North America accounts for 80% of global research. In addition, the revenue share of this region has grown due to the growing demand for illness treatment items.
As a result, North America now dominates the worldwide biologics market, with a revenue share of over 40% expected by the end of 2024. Intensive R&D efforts, novel medication formulations, and a significant number of clinical studies focusing on big-molecule drug development contribute to the market's growth in this area. Furthermore, the prospect of favorable returns due to biologics' premium price will encourage investment in the coming years.
During the anticipated time, the U.S biologics market will lead the North American market. With the COVID-19 epidemic spreading, firms in the United States are rushing to create vaccines. A Phase 1 clinical study to investigate an experimental immunization to protect against COVID-19 commenced in March 2020 at Seattle's Kaiser Permanente Washington Health Research Institute (KPWHRI). Scientists from the National Institute of Allergy and Infectious Diseases (NIAID) and Moderna Inc. work on the vaccine.
KEY MARKET PLAYERS
A few notable companies in the North American biologics market include
- Johnson & Johnson (J&J)
- F. Hoffmann-La Roche
- Bristol-Myers Squibb
- GlaxoSmithKline
- AbbVie
- Amgen
- Sanofi
- Eli Lilly and Company
- Merck & Co.
- Pfizer Inc.
MARKET SEGMENTATION
This research report on the North America Biologics Market has been segmented & sub-segmented into the following categories.
By Source
- Microbial
- Mammalian
- Others
By Product
- Monoclonal Antibodies
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others
By Biologics Manufacturing
- Outsourced
- In-house
By Disease Category
- Oncology
- Infectious Diseases
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
By Country
- US
- Canada
- Rest of North America